How to Help International Companies Launch Healthcare Products into the U.S. Market

Many foreign-based companies are developing innovative healthcare products with plans to enter the U.S. market. However, the U.S. healthcare landscape is uniquely complex, requiring careful navigation to ensure a successful product launch. A critical consideration is understanding the wide array of U.S reimbursement models used to finance and manage patient care.

Unlike many countries with centralized healthcare systems, the U.S. operates through a fragmented structure that combines federal programs (e.g., Medicare and Medicaid) with a diverse array of private insurers. This creates challenges for companies unfamiliar with the complexities of:

  • Payment models such as Fee-for-Service (FFS) and Value-Based Care (VBC), each with complex considerations for product positioning and impact
  • Pricing, coding, and reimbursement guidelines dictated by both public and private payers
  • Provider adoption requirements, including rigorous demands for clinical and financial validation, especially for emerging technologies like artificial intelligence

FHG helps foreign companies understand and align their value proposition with the financial realities of the U.S. healthcare system. Our expertise guides clients in positioning their product’s economic impact clearly and convincingly, guiding the way for market entry, provider adoption, and long-term success.

Next Steps in Working with FHG for a Successful Healthcare Product Launch

Navigating U.S. reimbursement models—whether Fee-for-Service (FFS) or Value-Based Care (VBC)—requires more than understanding the terminology. It demands a strategic pathway to quantify your product’s financial value in a way that resonates with diverse stakeholders.

FHG is here to help. Whether your goal is to demonstrate revenue-generating potential under Fee for Service or cost savings in a Value-Based Care framework, we provide the expertise to guide you through the financial modeling process.

Schedule a strategic conversation with FHG to:

  • Share your solution and its financial value drivers within the U.S. healthcare market
  • Clearly define your target Customer and what you want to communicate in your sales messaging
  • Determine the most effective way to financially model your product’s impact for a targeted customer segment

FHG will then develop a customized Healthcare ROI Assessment tool to help you communicate the clinical and economic financial impact, and the resulting ROI, your product delivers.

By working with FHG, you gain the clarity and confidence to position your solution within the complex U.S. healthcare ecosystem, driving product adoption, revenue growth, and sustained market success.

Contact FHG

Working with The FiscalHealth Group

What is the primary objective of a Healthcare ROI Assessment sales tool created by FHG?

FHG ROI Assessment sales tools are designed to help you accurately quantify the financial value your solutions can generate in the complex U.S. healthcare market. We do this by helping sales organizations confidently engage CFOs and other economic buyers to:

  • Understand the ROI your solutions can provide in both Fee-for-Service (FFS) and Value-based Care (VBC) U.S. reimbursment models
  • Sell on the ROI of your solutions instead of the price
  • Differentiate your solutions from your competition
  • Protect your margins – minimize discounts
  • Close more deals!

What do international companies struggle understanding the most?

Many of the organizations we engage with are deeply committed to reducing unnecessary episodes of care. Yet in the U.S. market, traditional Fee-for-Service (FFS) reimbursement remains dominant—rewarding greater volume. The FiscalHealth Group supports international companies by building ROI Assessment models that account for both Fee-for-Service (FFS) and Value-Based Care (VBC) frameworks, ensuring relevance across diverse payment landscapes. We also navigate the added complexity of payer segmentation, including Traditional Medicare, Medicare Advantage, and commercial insurance—each with distinct reimbursement methodologies and financial implications.

Other than reimbursement, what other factors need to be considered for international companies?

Many of our ROI assessment models are designed for flexibility—applicable across both U.S. and international markets. When tailoring for different geographies, we account for key variables such as physician compensation (often significantly higher in the U.S.), benefits and FICA taxes (unique to the U.S.), currency differences, and the absence of encounter-based reimbursement in many regions. We also factor in country-specific regulatory requirements, penalties, and other structural nuances to ensure relevance and accuracy across diverse healthcare systems.

What solutions are international companies typically trying to introduce into the U.S. market?

We typically partner with foreign-based startups at the forefront of emerging technologies—particularly in areas like AI, which can drive cost reduction, boost productivity, and expand patient volume. We also support U.S.-based companies with international operations by designing ROI Assessment models tailored to the unique dynamics of foreign markets, ensuring relevance across diverse healthcare systems and reimbursement structures.